Vida Health, a startup providing virtual chronic-conditions-management programs, has raised $25 million in new funding. Ally Bridge Group (ABG) led the raise, which also saw returning investors like AME Cloud Ventures, Aspect Ventures, Canvas Ventures, NGP Capital, Webb Investment Network and Workday Ventures.

Vida's approach combines live health coaches and therapists with a data-driven mobile platform. Among the conditions its programs help manage, prevent or reverse are diabetes, pre-diabetes, hypertension, obesity, depression and anxiety.

The company will be using its funds to meet the growing demand for virtual care services – and in particular mental health care – triggered by COVID-19.

“The COVID-19 pandemic has made it obvious that continuous, comprehensive, virtual care, is playing a key, ever-increasing role in healthcare,” ABG Founder, CEO and CIO Frank Yu said in a statement. “With a robust holistic product platform, a provider network that encompasses the United States, and best-in-class outcomes in programs ranging from weight loss to diabetes to heart diseases management, we believe that Vida Health is well positioned to play a leading role in transforming healthcare."

Particle Health, a New York City-based startup focused on patient data access, raised $12 million this week. The Series A round was led by Menlo Ventures, and included prior institutional backers such as Collaborative Fund, Story Ventures and Company Ventures. Individual angel investors hailing from Flatiron Health, Clover Health, Plaid, Petal and Hometeam also took part.

Particle Health offers digital health stakeholders such as telemedicine providers or pharmacies an API that securely and quickly pulls patient records.

"Clumsy information sharing has taxed US healthcare for decades, but new rules against Information Blocking establish patients' rights to access their medical data via API," Greg Yap, partner at Menlo Ventures, said in a statement. "Particle Health's technology platform is the first to deliver simple, secure, scalable and comprehensive access to healthcare data. The combination of portability and privacy will enable the next generation of digital health applications. We're excited to join Particle in the quest to enable health data interoperability, ultimately reducing costs and improving outcomes for patients."

The company did not disclose how it would be employing its new funds.

Oakland, California-based Dascena Inc. has closed $50 million in Series B financing. The round was led by Frazier Healthcare Partners, and also saw collections from Longitude Capital, Euclidean Capital and another undisclosed investor. The round will help the company continue development on its suite of diagnostic machine learning algorithms for clinician decision support.

"Machine learning is transforming how we solve problems across industries, and by applying this technology to healthcare, we will enhance the quality and efficiency of patient care," Ritankar Das, CEO and founder of Dascena, said in a statement. "Our flagship sepsis algorithm, InSight, has produced significant decreases in mortality and hospital length of stay among patients with sepsis. In U.S. hospitals, over a quarter million patients die of sepsis each year. We believe that our InSight algorithm can have a substantial impact in this arena."

Digital medical microscopy startup Scopio Labs has wrapped up a $16 million Series B funding round. Olive Tree Venture headed the raise, which also saw contributions from Aurum Ventures, OurCrowd, LR Group and others. This brings the company's total raise to $30 million.

The Israeli company looks to automate imaging of full microscopy samples into digital scans, and offers a platform that includes remote-consultation support.

To expand commercial operations in the U.S. and Europe, it said that it will be using the raise to further its manufacturing and sales efforts, as well as to further develop its clinical trial pipeline.

"We are delighted by the additional investor support that reinforces our vision and dedication to advancing clinical and research fields into new arenas through microscopy, a cornerstone of science and medicine which has been held back from joining the digital revolution by the complexity of scanning samples easily and at such high resolution," Itai Hayut, cofounder and CEO at Scopio Labs, said in a statement.